Meet Kevin Myant. Image Our business aims to develop novel strategies for targeting cancer by disrupting a process called RNA splicing. The Team Kevin Myant About Me I'm a Cancer Research Scientist based and the Edinburgh Cancer Research Centre. I am interested in developing novel RNA-based anti-cancer therapies. Problem Therapy resistance is the biggest clinical problem in cancer management. We are trying to develop new therapies that overcome this problem. Solution Our research suggests that targeting a process called RNA splicing can stop tumour cells dividing and spreading. We are developing therapies that target RNA splicing to both directly prevent tumour growth and also help target the bodies own immune defences against it. Market Our primary disease market is colorectal cancer, which affects nearly 2 million people worldwide annually. However, our proposed solution could be applicable for multiple cancer types, expanding the potential market even further. Contact Kevin Myant Profile Image This article was published on 2024-06-06
